Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma

Bud Bilanich
Success Coach

David Linetsky
Point-of-Care Marketing

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Liz Kane
Impactful Strategy

Joey Cohen
Medication Adherence